Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H23N5O |
| Molecular Weight | 349.4295 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(CC(=O)NC1=NC(=CN1)C2=NC=CC=C2)C3=C(C)C=C(C)C=C3C
InChI
InChIKey=JPLQUMVXDBHHSG-UHFFFAOYSA-N
InChI=1S/C20H23N5O/c1-13-9-14(2)19(15(3)10-13)25(4)12-18(26)24-20-22-11-17(23-20)16-7-5-6-8-21-16/h5-11H,12H2,1-4H3,(H2,22,23,24,26)
| Molecular Formula | C20H23N5O |
| Molecular Weight | 349.4295 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:27:41 GMT 2025
by
admin
on
Tue Apr 01 16:27:41 GMT 2025
|
| Record UNII |
4H59NZJ57G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1356959-16-4
Created by
admin on Tue Apr 01 16:27:41 GMT 2025 , Edited by admin on Tue Apr 01 16:27:41 GMT 2025
|
PRIMARY | |||
|
56652611
Created by
admin on Tue Apr 01 16:27:41 GMT 2025 , Edited by admin on Tue Apr 01 16:27:41 GMT 2025
|
PRIMARY | |||
|
4H59NZJ57G
Created by
admin on Tue Apr 01 16:27:41 GMT 2025 , Edited by admin on Tue Apr 01 16:27:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
WN1316 has high blood-brain-barrier permeability and water solubility, and boosts both neuronal apoptosis inhibitory protein (NAIP) and NF-E2-related factor 2 (Nrf2) which governed glutathione (GSH)-related anti-oxidation pathway protecting motor neurons against oxidative injuries. Post-onset oral administration of low dose (1-100 undefinedg/kg/day) WN1316 in ALS(SOD1(H46R)) and ALS(SOD1(G93A)) mice resulted in sustained improved motor function and post onset survival rate. Immunohistochemical analysis revealed less DNA oxidative damage and motor neuronal inflammation as well as repression of both microgliosis and astrocytosis, concomitant down regulation of interleukin-1.BETA. and inducible nitric oxide synthase, and preservation of the motoneurons in anterior horn of lumbar spinal cord and skeletal muscle (quadriceps femoris). Thus, WN1316 would be a novel therapeutic agent for ALS.
|
||
|
ACTIVE MOIETY |
Originator: Neugen Pharma, Wakunaga Pharmaceutical; Developer: Neugen Pharma; Class: Acetamide, Cytoprotective, Imidazole, Neuroprotectant, Pyridine, Small molecule; Mechanism of Action: Antioxidant, Astrocyte inhibitor, Glial cell inhibitor, Neuronal apoptosis-inhibitory protein stimulant, NF E2 related factor 2 stimulant; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phases: Phase I for Amyotrophic lateral sclerosis
Most Recent Events: 05 Mar 2015 Neugen Pharma completes an investigator-sponsored phase I trial in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054), 10 Sep 2014 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054), 01 Sep 2013 Preclinical trials in Amyotrophic lateral sclerosis in Japan (PO)
|
||
|
ACTIVE MOIETY |
Official scientific title of the study: An investigator initiated clinical trial in healthy adults to evaluate safety and pharmacokinetics of WN1316, a candidate drug of amyotrophic lateral sclerosis
Results: Oral doses of WN1316 were well tolerated in Japanese healthy male subjects up to 600 micrograms/body (equivalent to the 10 micrograms/kg/day minimum effective dose on ALS mouse model) and no significant safety issue was not observed. In regards to pharmacokinetics, it was confirmed that WN1316 was absorbed and excreted from the body but linearity could not be confirmed owing to too small doses.
|
||
|
ACTIVE MOIETY |
Drug: WN 1316(Primary); Indication: Amyotrophic lateral sclerosis; Focus: Adverse reactions, Pharmacokinetics; Most Recent Events: 05 Mar 2015 According to the University Hospital Medical Information Network - Japan record, status changed from recruiting to completed., 11 Sep 2014 New trial record
|
